ID   N6-KU70-2-DG
AC   CVCL_C4PE
DR   Wikidata; Q116049861
RX   PubMed=36162731;
CC   Population: Caucasian.
CC   Knockout cell: Method=CRISPR/Cas9; HGNC; 4055; XRCC6.
CC   Sequence variation: Gene fusion; HGNC; 50800; DUX4 + HGNC; 5477; IGH; Name(s)=IGH-DUX4; Note=The translocation occurs in the silenced IGH allele (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C9143; Adult B acute lymphoblastic leukemia
DI   ORDO; Orphanet_99860; Precursor B-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0092 ! NALM-6
SX   Male
AG   19Y
CA   Cancer cell line
DT   Created: 15-12-22; Last updated: 30-01-24; Version: 4
//
RX   PubMed=36162731; DOI=10.1016/j.bbagen.2022.130246;
RA   Ghosh D., Nilavar N.M., Raghavan S.C.;
RT   "A novel KU70-mutant human leukemic cell line generated using
RT   CRISPR-Cas9 shows increased sensitivity to DSB inducing agents and
RT   reduced NHEJ activity.";
RL   Biochim. Biophys. Acta 1866:130246.1-130246.11(2022).
//